Skip to Content

LEP-ETU Approval Status

FDA Approved: No
Brand name: LEP-ETU
Generic name: Liposome Entrapped Paclitaxel
Company: Insys Therapeutics, Inc.
Treatment for: Ovarian Cancer

LEP-ETU (liposome entrapped paclitaxel) is an easy-to-use (ETU) liposomal formulation of paclitaxel (Taxol) in development for the treatment of ovarian cancer.

Development Status and FDA Approval Process for LEP-ETU

DateArticle
Jan 26, 2015Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel for the Treatment of Ovarian Cancer
Sep 29, 2005NeoPharm Announces LEP-ETU Project Update

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide